The S&P 500 and the Dow were flat in early morning trading Monday after an explosion rocked New York’s Port Authority, one of the city’s busiest commuter hubs.
Police confirmed one suspect was in custody but had yet to identify the device used. Local news channel WABC cited police sources as saying a possible pipe bomb detonated in a passageway below ground at Port Authority.
“When you see one of these events in a major city, you get a little cautious tone. But it’s never enough to really rout a stock market intraday,” said Michael Antonelli, managing director, institutional sales trading at Robert W. Baird in Milwaukee.
At 9:37 a.m. ET, the Dow Jones Industrial Average was down 8.85 points, or 0.04 percent, at 24,320.31; the S&P 500 was up 1.14 points, or 0.04 percent, at 2,652.64, and the Nasdaq Composite was up 18.81 points, or 0.28 percent, at 6,858.89.
Technology stocks led the gainers on the S&P 500, rising 0.41 percent, while financial stocks were the biggest losers. Energy stocks also rose on the back of a rise in oil prices after the explosion.
Interest in the surge in bitcoin and opening of futures trading continued to fuel bets on crypotcurrency-related stocks, many of which have risen exponentially in value in the past three months. Shares of Marathon Patent, Riot Blockchain, Overstock.com and Xunei were up between 10 percent and 24 percent. Bitcoin futures jumped more than 20 percent in the US debut Sunday, which backers hope will encourage wider use and give legitimacy to cryptocurrency.
Market expectations of an interest rate hike from the Federal Reserve later this week firmed up after a jobs report showed that the economy added 228,000 jobs in November.
However, sluggish wage growth has raised doubts about the central bank’s plan to raise interest rates three times in 2018.
“We’ve got the Fed meeting where it’s pretty much factored in that the Fed is going to be raising rates. The concern is what they are going to say about going forward,” said Scott Brown, chief economist at Raymond James in St. Petersburg, Florida.
Bluebird Bio shares rose about 19.2 percent after its experimental gene-modifying immunotherapy drug co-developed with Celgene received positive responses in early stage study. Celgene was up 2.4 percent.
Advancing issues outnumbered decliners on the NYSE by 1,487 to 1,046. On the Nasdaq, 1,502 issues rose and 894 fell.